Status:

TERMINATED

Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis

Lead Sponsor:

Copenhagen University Hospital, Hvidovre

Collaborating Sponsors:

University of Copenhagen

Aarhus University Hospital

Conditions:

Liver Cirrhoses

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

In a randomized, doubleblind and placebo-controlled trial we assess both clinical and cellular effects of atorvastatin in patients with liver cirrhosis. 162 participants will be allocated to atorvast...

Detailed Description

Introduction Several studies have demonstrated the beneficial effects of statins in vascular and heart disease. Statins have antithrombotic effects, decrease oxidative stress and inflammation at the v...

Eligibility Criteria

Inclusion

  • Patients in the age of 18 to 80 years
  • Patients with liver cirrhosis, diagnosed by liver biopsy or ultrasound or CT scan of the liver and clinical biochemistry compatible with cirrhosis within the past 3 months.
  • In women, documented absence of pregnancy and unless in menopause commitment to use adequate contraception.
  • Clinically significant portal hypertension with a hepatic venous pressure gradient measured by liver vein catheterization \>10 mmHg.
  • Ability to read and understand project information in Danish and give written, informed consent.

Exclusion

  • People treated with statins within the last year.
  • People with liver cirrhosis, with a clinically verified infection (standard biochemistry, culture) within the last four weeks.
  • Pregnancy or lactation.
  • Hepatocellular carcinoma
  • HIV infection and treatment with protease inhibitors
  • People in whom the clinician and investigators may have reason to doubt compliance to trial medication
  • Clinical and biochemical signs of hepato-renal syndrome defined by current guidelines (EASL) within the last 14 days
  • A MELD score above 23, or Child-Pugh score higher than 13.
  • Hepatic encephalopathy grade 2 or higher

Key Trial Info

Start Date :

November 8 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 10 2023

Estimated Enrollment :

78 Patients enrolled

Trial Details

Trial ID

NCT04072601

Start Date

November 8 2019

End Date

January 10 2023

Last Update

January 13 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gastro Unit, medical Division, University Hospital Hvidovre

Hvidovre, Danmark, Denmark, 2650